Tandem Diabetes Care, Inc. delivered strong Q4 '25 results, with revenue and gross margin beats driving a 32% stock surge.

Fintel reports that on February 23, 2026, Lake Street upgraded their outlook for Tandem Diabetes Care (NasdaqGM:TNDM) from ...

Tandem Diabetes Care (NASDAQ:TNDM) reported record fourth-quarter and full-year 2025 results while outlining a major shift in ...

NICE recommends SGLT-2 inhibitors with metformin at diagnosis, citing major cardiovascular, renal, and mortality benefits.

Ascensia Diabetes Care, a global diabetes care company and subsidiary of PHC Holdings Corporation (TSE: 6523), today announced the appointment of Peter Bodlund as President and Chief Executive Officer ...

“MASLD and T2DM represent intersecting global epidemics with substantial clinical and public health implications,” wrote the ...

Participation in accountable care organizations shows better diabetes care outcomes for patients in rural areas than for those in urban settings.

The new NICE guidance recommends that most people should now be offered metformin along with an SGLT-2 inhibitor from the start, while also advising that they get a slow-release formulation of ...

Vosseller announced, "Our 2026 U.S. sales are expected to be in the range of $730 million to $745 million based on growth in pump shipments of 10% to 11% year-over-year. This incorporates $70 million ...

CLEVELAND, Ohio — Patients with Type 1 diabetes have lost the specialized pancreatic cells that produce insulin, putting them ...